Podcasts about Maintenance therapy

In this two-part series host Jonathan Sackier is joined by Bradley Monk, a pioneering figure in gynaecologic oncology. In Part 1, they discuss key updates from the European Society of Gynaecological Oncology (ESGO) Congress, including the updated ESGO-ESTRO-ESP endometrial cancer guidelines and the latest results from the KEYLYNK-001 study in ovarian cancer. With reflections from his three-decade career, Monk provides actionable takeaways for clinicians and researchers alike. Stay tuned for Part 2, where they delve into insights from SGO 2025.  Timestamps:  00:00 - Quickfire questions 04:55 - Career milestones 07:10 - ESGO 2025 standout sessions 09:52 - KEYLYNK-001 trial & takeaways 13:52 - New endometrial cancer staging   

In this week's episode, we'll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickle cell trait, and wild-type hemoglobin. Featured Articles:Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia Babesiosis and Sickle Red Blood Cells: Loss of Deformability, Heightened Osmotic fragility and Hyper-vesiculation 

This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences. Topics discussed include: Current confusion about the clinical heterogeneity within the intermediate-risk patient group The best way to select adequate intravesical therapy for this group The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy *References Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208. European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/ Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683. Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695. Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.

A recent #study from Assiut University Hospital in Egypt, published in #Oncotarget, presents a promising strategy for patients with metastatic #colorectalcancer (mCRC). The #research introduces a gentler yet effective maintenance therapy that may extend survival, enhance quality of life, and offer a more accessible treatment option for mCRC patients worldwide. The Challenge of Treating Metastatic Colorectal Cancer Colorectal cancer is one of the most common causes of cancer-related deaths worldwide. When it spreads to other parts of the body—a stage known as mCRC—it becomes much more difficult to treat. At this stage, clinicians often use strong drug combinations like FOLFOX or CAPOX, which mix chemotherapy drugs to stop cancer growth. FOLFOX combines three drugs given intravenously, while CAPOX includes two of the same drugs, with one taken as a pill. While effective, these treatments can cause serious side effects. For example, one of the main drugs, oxaliplatin, can lead to nerve damage, making it painful or difficult to use the hands and feet. Fatigue, diarrhea, and other issues are also common. Over time, these side effects may force clinicians to stop or adjust the treatment, even if it is working. That is where maintenance therapy comes in. After the cancer is controlled, clinicians often switch to a gentler treatment plan to keep it from returning. The challenge is finding a therapy that continues to work without causing too many side effects, especially in places where access to expensive or intensive treatments is limited. Full blog - https://www.oncotarget.org/2025/05/07/panitumumab-and-low-dose-capecitabine-a-promising-maintenance-therapy-for-metastatic-colorectal-cancer/ Paper DOI - https://doi.org/10.18632/oncotarget.28687 Correspondence to - Doaa A. Gamal - doaaalygamaal@gmail.com Video short - https://www.youtube.com/watch?v=wuPSS0EdK-8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28687 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Panitumumab, maintenance, colorectal cancer, Capecitabine About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Anisha B. Dua, MD, MPH and Duvuru Geetha, MD discuss evolving strategies in maintenance therapy for ANCA-associated vasculitis. In keeping with the goal of achieving sustained remission and minimizing relapse, they provide insight into the duration and dosing of maintenance therapy, as well as treatment options and monitoring.

In this episode, host Ken Vinacco talks with Bobby Hand about the role and intricacies of skilled maintenance therapy for individuals with degenerative diseases. Skilled maintenance therapy is the care that physical therapists can provide to individuals who have conditions with no curative treatment. Bobby and Ken delve into how PTs can provide therapy that impacts the individual's quality of life, even when they are not expected to make improvements. Bobby shares examples from his clinical practice, and tips for making it work for your practice.    The Degenerative Diseases Special Interest Group is part of the Academy of  Neurologic Physical Therapy – www.neuroPT.org  For questions about this podcast, please contact neuroddsig@gmail.com   Show notes available here: https://app.box.com/s/h12shsaxu8lpaaxabxk798qd96rpud41

Long-acting muscarinic antagonist and long-acting β2-agonist combination for the treatment of maintenance therapy–naïve patients with chronic obstructive pulmonary disease: a narrative review

In this episode, Improving Survival With HMA Therapy in AML, Dr. Amer Zeidan and Dr. Guillermo Garcia-Manero discuss the latest clinical trial evidence for using hypomethylating agents as maintenance therapy for AML patients as well as which patients will benefit most from these therapies. Visit https://suiteweb.atpointofcare.com/#library/mds-aml/2646.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

View Activity Infrmation…

In this week's episode we'll discuss the outcomes of younger patients with mantle cell lymphoma experiencing late relapse; learn more about mass spectrometry-based assessment of M-protein in peripheral blood during maintenance therapy in multiple myeloma and discuss in vivo CAR T-cell generation in non-human primates using lentiviral vectors.Featured Articles: Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD studyMass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy inmultiple myelomaIn vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand

The process of weaning our patients off biologic disease-modifying antirheumatic drug (b-DMARD) therapy is not unfamiliar in our clinics. However, when attending to our patients, many complications and questions arise. Specific guidance is needed, but where do we turn? Thankfully, our latest guest, Dr. Paul Emery, may have some answers. His latest study, Predicting Flare in Patients With Rheumatoid Arthritis in Biologic Induced Remission, on Tapering, and on Stable Therapy attempted to “identify predictors of flare in patients in stable b-DMARD–induced clinical remission”. Let's dive in together and see what he and his team have found! 

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed:1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation): https://pubmed.ncbi.nlm.nih.gov/28742454/ 2. Myeloma XI RCT (lenalidomide vs observation): https://pubmed.ncbi.nlm.nih.gov/30559051/ 3. Outcomes of lenalidomide maintenance stratified by cytogenetic subgroups (Secondary analysis of Myeloma XI): https://pubmed.ncbi.nlm.nih.gov/36564045/ 4. Canadian real-world data on lenalidomide maintenance: https://pubmed.ncbi.nlm.nih.gov/33054120/ 5. FORTE trial (Carfilzomib-Lenalidomide vs Lenalidomide): https://pubmed.ncbi.nlm.nih.gov/34774221/ 6. ATLAS trial (Carfilzomib-Lenalidomide-Dexamethasone vs Lenalidomide): https://pubmed.ncbi.nlm.nih.gov/36642080/ 7. Differential censoring and potential impact on PFS in ATLAS trial: https://pubmed.ncbi.nlm.nih.gov/37433885/ 8. GEM2014 (Ixazomib-Lenalidomide-Dexamethasone vs Lenalidomide-Dexamethasone): https://ashpublications.org/blood/article-abstract/142/18/1518/497188 9. MASTER trial (MRD-guided treatment de-escalation): https://pubmed.ncbi.nlm.nih.gov/37776872/ 10. Outcomes after MRD-guided treatment discontinuation (Secondary analysis of GEM2014MAIN trial): https://pubmed.ncbi.nlm.nih.gov/37506339/

Who wants to talk about a fun topic?! What if learning about Medicare Maintenance Therapy actually was fun and didn't make you fall asleep? Well, that's what you're going to get on today's episode! We sat down with our favorite Medicare Utilization Reviewer, Dr. Robbie Leonard, PT, DPT, CHC to discuss the hot and sticky points about Medicare skilled therapy. We know a LOT of US-based therapists have questions and we're here to help! In today's show we discuss some common misconceptions about using Medicare for therapy so we can help you pass an audit and stay out of trouble!  Some of the topics covered today include: Medicare's definition of medical necessity and when it does and does not cover services The only 2 standards under which you can treat - restorative and maintenance and what they each mean When do to restorative and when to do maintenance and why you should NOT mix the two The questions you should ask yourself every time you see a patient: Could what I'm doing be provided by a caregiver or technical person that I train? If yes, it should not be billed at all. Unfortunately it doesn't matter whether there is a qualified caregiver available or not. How you get audited: You can be flagged to be audited because your data profile looks different. If you always use or never use KX you can be audited for being an outlier. You should never stop seeing people just because they've reached the threshold. This can be a red flag! What you should NEVER say to a patient about their Medicare dollar usage When it is and is not appropriate to stop providing skilled therapy (hint: it doesn't have to do with where the patient is in their threshold spend!) How to know if you can provide more therapy to a person who's reached their threshold for the year: evaluations will always be covered!  Why you should not be concerned (or turn away) a patient who has used up to their Medicare threshold or beyond Initial threshold What about Medicare and cash? If you're providing a covered service you cannot opt out of Medicare as a therapist. You are legally obligated to file a claim. What does wellness look like then? What does a reasonable time frame actually look like? Jimmo settlement CMS Medicare regulations all US therapists should read: Medicare Benefit Policy Manual Chapter 15, Section 220.2 D NeuroSpark members find the Parkinson Focus Track call recording with Robbie HERE with additional information covered Find Robbie at: robbie@8150advisors.com **Please note, the contents in this episode are for educational purposes and should not be considered legal advice

Maintenance therapy for patients with acute myeloid leukemia, particularly those who are ineligible for transplant, can be critical to treatment outcomes and quality of life for patients. In this episode, CANCER BUZZ speaks with Thomas LeBlanc, MD, hematologic oncologist, associate professor of Medicine, and associate professor in Population Health Sciences at Duke Cancer Institute, about the importance of keeping patients with acute myeloid leukemia in first remission as long as possible through maintenance therapy.   “You have to be aware of the benefits of maintenance therapy…and for patients who are being considered for transplant but who do not end up getting a transplant, it should really be the default option that those patients receive a maintenance therapy.” –Thomas W. LeBlanc, MD   Guest:         Thomas W. LeBlanc, MD Hematologic Oncologist, Associate Professor of Medicine, Associate Professor in Population Health Sciences Duke Cancer Network, Duke Cancer Institute Durham, North Carolina   This is the fourth and final episode of a four-part series developed in connection with the ACCC education program Achieving and Maintaining Better Outcomes for Patients with Acute Myeloid Leukemia. This episode was made possible with support by Bristol Myers-Squibb.   Additional Reading/Sources Improving Care Delivery for Transplant-Ineligible Patients with AML AML Care Coordination in the Community Setting [Video Podcast] Critical Conversation Strategies for Patients with AML [Video Podcast] Strategies to Addressing Disparities in Patients with AML [Video Podcast] Shared Decision-making in Acute Myeloid Leukemia Achieving and Maintaining Better Outcomes for Patients with AML Talking about Acute Myeloid Leukemia (Cancer Support Community) Shared Decision-making: Practical Implementation for the Oncology Team (ACCC)

View Activity Information …

Allison has some great ideas for Gabe's movie. A listener writes in to ask about no longer "needing" therapy but still wanting to go. Poet Maya Williams joins the show to talk about their new book "Refused A Second Date," intergenerational dating patterns and the process of writing very personal poetry. Finally, should you work with your friends? Or is that a disaster waiting to happen?  Watch clips and the full TLDRI episodes AND listen to the full Wednesday episodes:https://www.patreon.com/justbetweenusThis has been a Gallison ProductionProduced by Melisa D. Monts and Diamond MPrint ProductionsPost-Production by Coco LlorensProduction Assistance by Melanie D. WatsonSupport this podcast at — https://redcircle.com/just-between-us/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Dr. Tobias Berg, an Associate Professor and Researcher from McMaster University explains Maintenance Therapy as a treatment option for AML and the factors that influence the decision to start this type of treatment.

Nilay Shah, MD is a clinician-scientist and Associate Professor in the Division of Hematology/Oncology/BMT at Nationwide Children's Hospital. His primary clinical focus is on pediatric solid tumors, including neuroblastomas, tumors of the kidneys, and rare solid tumors of childhood. His research focuses on the molecular drivers of pediatric cancers and how new treatment approaches can be taken to better target those drivers. In this role, he works to identify new uses of currently available anticancer treatments, including drugs originally developed for use against cancers in adults. He serves as Associate Director for Liver Tumor, Kidney Tumor, Germ Cell, and Neuroblastoma Targeted Therapies, and is currently the Sponsor and Study Principal Investigator the CaboMain trial, a Phase 2 study evaluating the efficacy of the oral anticancer agent cabozantinib as a maintenance therapy for ultra-high-risk solid tumors. He also serves as co-director of the Cancer Genetics Program. This program serves to advance the use of genetic and genomic evaluations for the benefits of patients. In this role, he sees patients in the Cancer Predisposition Clinic for evaluation, surveillance, and management of patients with genetic alterations that predispose to cancer development. He also consults on patients for precision oncology, partnering with the Institute for Genomic Medicine to identify therapeutic approaches based on patient tumor and germline genomics. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Please visit answersincme.com/FXY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in psychiatry discusses atypical antipsychotics in the treatment of bipolar I disorder. Upon completion of this activity, participants should be better able to: Identify strategies to improve the diagnostic accuracy of bipolar I disorder (BD-I); Review the clinical profiles of atypical antipsychotics for the treatment of BD-I; and Outline opportunities to individualize treatment for patients with BD-I, based on patient-, disease-, and drug-specific characteristics.

In today's episode, @coach.noush_dpt talks about Maintainence Therapy under CMS guideline and offers some clinical pearls for documentation.   Want to make sure you stay on top of all things geriatrics? Go to https://MMOA.online to check out our Free eBooks, Lectures, & the MMOA Digest!  

We continue our myeloma series, transitioning our discussion from autologous stem cell transplant to maintenance therapy for myeloma.Content:- Why do we use revlimid (lenalidomide) maintenance?- What about in high risk patients?- What is the role of MRD testing?- What about daratumumab in the maintenance setting? This episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co.Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Drs. Fernando Fervenza, Marta Casal Moura, and Ulrich Specks discuss the results of their study, "Maintenance of Remission and Risk of Relapse in Myeloperoxidase Positive Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Renal Involvement."

Alon Altman, MD, FRCSC - Aiming for Above Par Outcomes in Advanced Ovarian Cancer: The Role of Frontline Maintenance Therapy With PARP Inhibitors

“For those without cancer or other illnesses, we often have a resolution or relief of this fatigue. ‘Oh, I'm just going to go to bed early and get a couple more hours of sleep tonight.' Or ‘I'm going to have a cup of coffee.' But for people with cancer, it's not an easy fix. People with cancer describe fatigue as something much more long-lasting,” ONS member Paula Anastasia, MN, RN, AOCN®, clinical nurse specialist for UCLA Health in Los Angeles, CA, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS. Anastasia discussed fatigue in patients with cancer undergoing PARP inhibitor maintenance therapy, management strategies, and nursing considerations. This podcast episode is supported by a sponsorship from AstraZeneca. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes NCPD contact hours are not available for this episode. Clinical Update: Ovarian Cancer Focus Group Summary ONS Get Up, Get Moving resources ONS Guidelines™ on Fatigue Oncology Nursing Podcast Episode 227: Biomarker Testing, PARP Inhibitors, and Oral Adherence During Ovarian Cancer Maintenance Therapy ONS Voice articles: Symptom Assessments: Use a Team-Based Approach to Inform Care and Optimize Outcomes Master the Essentials of Effective Communication What the Evidence Says About Music Therapy for Cancer-Related Fatigue Acupuncture for Cancer-Related Fatigue Biomarkers Are Advancing Understanding of Cancer-Related Fatigue Clinical Journal of Oncology Nursing articles: The Impact of a Nurse-Led Exercise Activity for Cancer-Related Fatigue in Patients With Leukemia Exercise Intervention: A Pilot Study to Assess the Feasibility and Impact on Cancer-Related Fatigue and Quality of Life Among Patients With High-Grade Glioma Oncology Nursing Forum article: The Effectiveness of Yoga on Cancer-Related Fatigue: A Systemic Review and Meta-Analysis National Comprehensive Cancer Network Guidelines > Supportive Care > Cancer-Related Fatigue ASCO Answers: Cancer-Related Fatigue To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “Fatigue is not necessarily life threatening, so I think unfortunately, it's underplayed at how disruptive it can be in somebody's quality of life and day-to-day life.” Timestamp (TS) 03:10 “For those without cancer or other illnesses, we often have a resolution or relief of this fatigue. ‘Oh, I'm just going to go to bed early and get a couple more hours of sleep tonight.' Or ‘I'm going to have a cup of coffee.' But for people with cancer, it's not an easy fix. . . . People with cancer describe fatigue as something much more long lasting.” TS 04:02 “I think it's really important when we educate our patients to let them know that this is a common side effect. Research tells us, and also patient experience, that fatigue does plateau after about four to eight weeks. It's not zero, but it gets much more manageable for our patients. So, I think priming our patients with what to expect can be very helpful.” TS 07:48 “I want patients to have some sort of physical activity. It doesn't have to be hours or marathons. Just a 10-minute walk in the morning and then maybe a 10-minute walk in the afternoon. Things like that. We try to, if possible, refer patients to a physical therapy-type setting initially, and that will help give them tools on how to be active and safe activities, and also gets them motivated. So, that's really helpful for patients.” TS 09:41 “I think it's important to assess the cause of the fatigue. Ruling out anemia, hypothyroidism, vitamin deficiencies, things like that. So, that is ruled out and we know what we're doing to our poor patient with the interventions; they've had surgery, they've had chemotherapy, now we're going to put them on a PARP inhibitor, all of these lifestyle changes.” TS 12:20 “I think since COVID-19, there's a lot more awareness of how much people have anxiety and depression. I think we're more in tune with that and how stressful life is, and that's not even having cancer and all of the challenges with that. So, I think that plays into it. Depression and anxiety can contribute to fatigue.” TS 16:53  “One of the biggest misconceptions about fatigue is that there's nothing that you can do about it. Just accept it. And I totally disagree with that. It's an undervalued side effect. It's not necessarily life threatening, but it's definitely something that can interfere with patients' day-to-day quality of life. So, we really need to address it. We need to assess, communicate, and plan for it.” TS 28:39

Maintenance therapy over the past several years has commonly included the use of Revlimid (lenalidomide) over a long period of time. Is more better? Does more maintenance therapy or certain combinations help extend remissions or help patients deepen their responses?  Ashraf Badros, MD, of the University of Maryland will join the HealthTree Podcast for Multiple Myeloma to talk with us about the rationale behind the AURIGA clinical trial using daratumumab and lenalidomide following stem cell transplant for patients who are still MRD positive.  Myeloma experts are working to identify more personalized approaches for each type of myeloma patient. We know that patients who are still MRD positive following high dose therapy are more likely to have shorter remissions and the use of a different maintenance therapy may help patients who aren't getting their deepest responses do better over time.  Thanks to our episode sponsor, Takeda Oncology

Maintenance therapy over the past several years has commonly included the use of Revlimid (lenalidomide) over a long period of time. Is more better? Does more maintenance therapy or certain combinations help extend remissions or help patients deepen their responses?  Ashraf Badros, MD, of the University of Maryland will join the HealthTree Podcast for Multiple Myeloma to talk with us about the rationale behind the AURIGA clinical trial using daratumumab and lenalidomide following stem cell transplant for patients who are still MRD positive.  Myeloma experts are working to identify more personalized approaches for each type of myeloma patient. We know that patients who are still MRD positive following high dose therapy are more likely to have shorter remissions and the use of a different maintenance therapy may help patients who aren't getting their deepest responses do better over time.  Thanks to our episode sponsor, Takeda Oncology

“We found that nurses still needed clarity of terminology and the rationale for germline, somatic, and homologous recombination deficiency testing,” ONS member Paula Anastasia, MN, RN, AOCN®, clinical nurse specialist for UCLA Health in Los Angeles, CA, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS. Anastasia discussed the findings of a July 2022 ONS focus group that she facilitated on PARP inhibitor therapy, biomarker testing and terminology, and oral medication adherence for patients with ovarian cancer. This podcast episode is supported by a sponsorship from AstraZeneca. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes NCPD contact hours are not available for this episode. Clinical Update: PARP Inhibitors Survey: 2022 Member Feedback on Ovarian Cancer Treatment Focus Group Outcomes ONS Biomarker Database ONS Genomics and Precision Oncology Learning Library ONS Guidelines™ to Support Patient Adherence to Oral Anticancer Medications Oncology Nursing Podcast episodes: Episode 215: Navigate Updates in Oral Adherence to Cancer Therapies ONS Voice articles: Oncology Nurses' Role in Translating Biomarker Testing Results Maintain Oral Adherence With ONS Guidelines™ Help Patients Understand Biomarker Test Results and Clinical Trials Options Genetic Counselors Help Patients and Providers Understand Biomarker Testing Goals and Results Nursing Considerations for Ovarian Cancer Survivorship Care An Oncology Nurse's Primer on Genomics and Biomarker Terminology Ovarian Cancer: Prevention, Screening, Treatment, and Survivorship Recommendations Clinical Journal of Oncology Nursing article: Shifting to a Biomarker Paradigm Across Cancer Care ONS video: Cancer Treatment Therapies Overview Oral Chemo Patient Education Sheets National Society of Genetic Counselors To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “We found in this focus group that nurses still needed clarity of terminology and the rationale for germline and somatic/homologous recombination deficiency (HRD) testing. They all shared that those who worked in the infusion center in general medical oncology offices as opposed to the specific gynecologic clinics, that they weren't as familiar with somatic and HRD terminology as you would suspect.” Timestamp (TS) 06:31 “As cancer care is evolving and patients are living longer and better, I think it's we nurses who are actually the ones that are doing these behind the scenes. The most common barriers that were consistently discussed across the board were cost and insurance approvals. . . . Other issues were access to the results. Results are not always being uploaded into the patient's medical record.” TS 09:51 “The nurses discussed wanting more knowledge of the mechanism of action with PARP inhibitors and how that alteration benefits patients with germline or somatic mutations. And most nurses did agree that their patients were offered germline testing at the time of diagnosis, but they were unclear as to when somatic or HRD testing was being done. . . . It was very inconsistent, so not all nurses knew where to find these results or to even know if it was done.” TS 16:54 “Education was key, and the nurses all agreed that it was important to identify who the appropriate patient would be that would most likely receive a clinical benefit, and who also would be following through or maintaining oral adherence. It was recommended to reinforce the side effects with the patients. . . . It was determined that patients should be informed that the goal of treatment of maintenance therapy was to prevent or decrease risk of recurrence.” TS 18:17 “It was recommended to assess patient adherence by asking open-ended questions. . . . The nurses agreed that the most common question to ask a patient would be: ‘How many doses did you miss this week? Or this month?' Recognizing that people miss doses, and it's not necessarily intentional, but it does happen, so we are validating and giving them permission to be honest with us.” TS 21:26 “I think having tools or resources—quick handouts—that they can give their patients that's like an easy guide, and they can review it with the patient, but the patient if they have questions can follow up. I think it's important to find out the patient's needs and how they learn best, on a video or paper, that sort of thing. . . . But the nurses also wanted quick-references guides, just an overview of what the indication is, what needs to be done prior to ordering this, and the mechanism of action.” TS 30:32

Marinos Dalakas discusses his most recent publication with Neurology on IVIg efficacy in GAD65 positive SPS patients.  Show references: https://nn.neurology.org/content/9/5/e200011 This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Stacey Clardy interviews Marinos Dalakas to discuss his most recent publication with Neurology on IVIg efficacy in GAD65 positive SPS patients. Read the full article here in Neurology.   This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Dr Monk discusses pertinent efficacy and safety data from the ATHENA-MONO trial, which evaluated first-line maintenance treatment with rucaparib in patients with stage III-IV high-grade ovarian cancer.

Maintenance Therapy in COPD: Optimising Benefit With Inhalers When Ability to Inhale is Compromised

Maintenance Therapy in COPD: Optimising Benefit With Inhalers When Ability to Inhale is Compromised

Maintenance Therapy in COPD: Optimising Benefit With Inhalers When Ability to Inhale is Compromised

Maintenance Therapy in COPD: Optimising Benefit With Inhalers When Ability to Inhale is Compromised

Maintenance Therapy in COPD: Optimising Benefit With Inhalers When Ability to Inhale is Compromised

This week, CancerNetwork® spoke with Muhammad Niazi, MD, resident in internal medicine at Staten Island University Hospital, and Alexander Bershadskiy, MD, attending physician at Staten Island University Hospital, about a meta-analysis published in ONCOLOGY titled, “Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.” The final analysis evaluated 3 randomized clinical trials. A fixed model showed a statistically significant improvement in overall survival for patients with metastatic castration-resistant prostate cancer treated with PARP inhibitors. The authors provided a detailed background on PARP inhibitors and further detailed the results of this research, focusing on survival increases with PARP inhibitor treatment for this patient population. Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Jacob Laubach, Dana-Farber Cancer Institute, Boston, US, and Peter Voorhees, Levine Cancer Institute, Charlotte, US. We asked, Daratumumab as maintenance therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM): What have we learned from GRIFFIN and CASSIOPEIA trials?In this podcast, Laubach and Voorhees discuss the findings from the randomized phase II GRIFFIN trial (NCT02874742) and the CASSIOPEIA trial (NCT02541383). Hosted on Acast. See acast.com/privacy for more information.

In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses therapeutic options for younger, fit patients with AML and no targetable mutations. Topics include:Induction chemotherapy and consolidation therapyUse of gemtuzumab ozogamicinManagement of sinusoidal obstruction syndrome  Nursing considerations for younger, fit patients with AMLPresenter:Ashley Leak Bryant, PhD, RN, OCN, FAANAssociate ProfessorSchool of NursingUNC Lineberger Comprehensive Cancer Center  University of North Carolina at Chapel HillChapel Hill, North Carolina 

What is the difference between retreatment and maintenance therapy? In this episode, the panellists discuss the role of TMS therapy after acute-phase treatment and the role of maintenance therapy.

Today we'll be speaking with Dee Kornetti and Cindy Krafft, owners and founders of Kornetti & Krafft Health Care Solutions. Both are recognized speakers in the areas of home health and physical therapy, bringing decades of expertise to offer compliance and revenue solutions. Today, we are talking about Cindy and Dee's newly updated book, The Guide to Delivery of Home-Based Maintenance Therapy . You can find this book on the Decision Health Store which is linked in the description.

On this episode of ASTCT Talks, we sit down with Dilan Patel, MD, advanced BMT fellow at Washington University School of Medicine in St. Louis. Patel was the lead author on a paper that explored minimal residual disease negativity and lenalidomide maintenance therapy, and how those were associated with superior survival outcomes for patients with multiple myeloma.

Hosted by: Dr. Deborah K. Armstrong Featuring: Dr. Eskander, Dr. O'Cearbhaill, Dr. Pothuri Continuing education (CE)—0.5 credits—is available through SGO ConnectEdLink: https://sgo.peachnewmedia.com/store/seminar/seminar.php?seminar=156603CE description: The Society of Gynecology Oncology designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation on each activity.

This week, we'll start off with a report that showed that ibrutinib may help to protect patients infected with COVID-19 from pulmonary injury due to the disease. Next, we'll move onto a report from the AACR Virtual Annual Meeting on talazoparib in patients with locally advanced or metastatic HER2-negative germline BRCA­-mutated breast cancer. Lastly, we'll review the FDA's approval of niraparib for patients with advanced ovarian cancer.Coverage of stories discussed this week on ascopost.com:Potential Protective Effect of Ibrutinib Against Pulmonary Injury in Patients With COVID-19AACR 2020: Final Overall Survival Results From the Phase III EMBRACA TrialFDA Approves Niraparib as Maintenance Therapy for Advanced Ovarian Cancer